2005
DOI: 10.1001/archneur.62.11.1728
|View full text |Cite
|
Sign up to set email alerts
|

Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease

Abstract: Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk for progression to Alzheimer disease (AD) and a population with different underlying pathologic conditions. Objective: To evaluate the potential roles of positron emission tomography with fluodeoxyglucose F 18 (18 FDG-PET) and memory scores in identifying subjects with aMCI and in predicting progression to dementia. Design, Setting, and Patients: Sixty-seven patients at European centers for neurologic and AD ca… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

12
193
1
4

Year Published

2007
2007
2015
2015

Publication Types

Select...
4
4
1

Relationship

0
9

Authors

Journals

citations
Cited by 262 publications
(210 citation statements)
references
References 22 publications
12
193
1
4
Order By: Relevance
“…Other techniques with promising diagnostic support are longitudinal measurements of wholebrain and/or hippocampal atrophy with structural MRI, cerebral blood flow with SPECT, and cerebral metabolism or amyloid imaging with PET scans. 16,18,38 Additionally, the combination of these diagnostic strategies seems to increase the predictive power to identify AD patients at the prodromal stages of the disease. 39 According to a recent task-force that proposed the revised NINCDS-ADRDA diagnostic criteria for research, 40 the presence of AD-compatible pathological findings, as indicated by one or more of these biomarkers, endorses the diagnosis of incipient (pre-dementia) AD given the clinical characterization of episodic memory impairment.…”
Section: Discussionmentioning
confidence: 99%
“…Other techniques with promising diagnostic support are longitudinal measurements of wholebrain and/or hippocampal atrophy with structural MRI, cerebral blood flow with SPECT, and cerebral metabolism or amyloid imaging with PET scans. 16,18,38 Additionally, the combination of these diagnostic strategies seems to increase the predictive power to identify AD patients at the prodromal stages of the disease. 39 According to a recent task-force that proposed the revised NINCDS-ADRDA diagnostic criteria for research, 40 the presence of AD-compatible pathological findings, as indicated by one or more of these biomarkers, endorses the diagnosis of incipient (pre-dementia) AD given the clinical characterization of episodic memory impairment.…”
Section: Discussionmentioning
confidence: 99%
“…Prior research suggests that anosognosia in MCI portends a faster rate of conversion to AD (Tabert et al, 2002). Additionally, PCC resting glucose metabolism and perfusion have been cited as prognostic indices of faster progression to AD (Anchisi et al, 2005;Huang et al, 2002;Kogure et al, 2000). Longitudinal follow-up of the current findings is needed to address the hypothesis that attenuated activity in cortical midline structures associated with anosognosia is predictive of faster cognitive and functional decline in MCI.…”
Section: Discussionmentioning
confidence: 99%
“…Investigations of resting brain function indicate that medial parietal regions such as the posterior cingulate cortex (PCC) show metabolic decline in MCI (Nestor et al, 2003), and longitudinal studies indicate that PCC metabolism and regional blood flow discriminate between individuals with MCI who soon develop AD and those who do not (Anchisi et al, 2005;Chetelat et al, 2003;Huang et al, 2002;Kogure et al, 2000). Additionally, fMRI studies of episodic recognition indicate that MCI participants show less PCC activation than age-matched controls (Johnson et al, 2005;Ries et al, 2006).…”
Section: Introductionmentioning
confidence: 99%
“…However, both these values were higher than 80 % in about half of the studies included [15][16][17][18][19][20], an accuracy that compares better with previous studies in which confirmation of underlying neurodegenerative pathology was obtained at autopsy. In the latter case, [ 18 F]FDG PET identified patients with AD with a sensitivity of 94 % and a specificity of 73 % [21].…”
Section: Results Of the Cochrane Reviewmentioning
confidence: 73%